Purdue Pharma L.P. (Purdue) announced that the company has partnered with MMCAP Infuse to provide buprenorphine and naloxone tablets CIII (generic Suboxone), a medication for opioid use disorder (MOUD), at low cost to correctional facilities for incarcerated individuals with opioid use disorder. MMCAP Infuse is a national cooperative group purchasing organization operated by the State of Minnesota, Office of State Procurement, for government facilities that provide healthcare services. Under the agreement, to increase access to treatment for incarcerated individuals, Purdue will provide for distribution approximately 1.25 million tablets at the cost of one penny ($0.01) per tablet.
FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose
Following the United States Bankruptcy Court approval of the Purdue Pharma L.P. chapter 11 plan of reorganization (the “Plan”), the name of the new company that will emerge was announced: Knoa Pharma LLC (pronounced “No-ah”). The name was selected by the Company’s creditors.
Following the United States Bankruptcy Court approval of the Purdue Pharma L.P. chapter 11 plan of reorganization (the “Plan”), the name of the new company that will emerge was announced: Knoa Pharma LLC (pronounced “No-ah”). The name was selected by the Company’s creditors.
NEW YORK (Reuters) - A group of 25 state attorneys general oppose a settlement of U.S. opioid probes being negotiated with Purdue Pharma LP and members of the wealthy Sackler family who own it, arguing the deal would improperly entangle state and local officials with future sales of the company’s addictive pain drug OxyContin.
NEW YORK (Reuters) - Purdue Pharma LP, the OxyContin maker controlled by members of the wealthy Sackler family, is nearing an agreement to plead guilty to criminal charges as part of a broader deal to resolve U.S. Justice Department probes into its alleged role in fueling the nation’s opioid crisis, six people familiar with the matter said.
A $50 Billion Opioid Deal Gets Backing From 7 More States (3)
Drugmaker Insys Therapeutics Inc on Thursday won court approval to sell its flagship fentanyl spray to a buyer who agreed to only market the drug for use by cancer patients, in response to concerns about the product’s role in fueling the opioid epidemic
Opioid Deal-Makers Cleared to Represent Cities Across U.S.
Morris & Dickson agreed to pay $22 million in civil penalties to settle U.S. government charges that it failed to report thousands of suspicious orders of the opioids hydrocodone and oxycodone.